Interview with Medical Prognosis Institute and Oncology Venture in Millionærklubben

2017-03-22

Hoersholm; March 22nd, 2017 - The Danish radio 24syv made an extensive interview with Medical Prognosis Institute A/S ("MPI") and Oncology Venture Sweden AB ("Oncology Venture") Tuesday 21st March 2017.

COO Ulla Hald Buhl explains about Medical Prognosis Institute and Precision Medicine and CEO Peter Buhl Jensen explains about Oncology Venture and drug development.

To hear the interview with MPI and OV, please visit:
http://www.radio24syv.dk/programmer/millionaerklubben/16358789/oncology-venture-klar-til-ny-emission


For further information, please contact:
CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.d.                              Ulla Hald Buhl, IR & Communication
E-mail: pbj@medical-prognosis.com                                                            E-mail: uhb@medical-prognosis.com
Telephone: +45 21 60 89 22                                                                        Telephone +45 21 70 10 49

About MPI
Medical Prognosis Institute advances personalized medicine by partnering with cancer drug developers to apply its DRP(TM) diagnostic platform to streamline and de-risk clinical trials and drug development via biomarker optimization, patient stratification, and development of companion diagnostics.

About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)
MPI's lead product, the DRP(TM) diagnostic platform, is a tool to develop tumor-derived gene signatures that may predict which cancer patients are highly likely responders to a given anticancer product. The DRP(TM) has been tested in 32 trials, where 26 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients had a positive effect of the treatment. The DRP(TM) platform has also been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anticancer drug.  Further to and in addition to this, individual patients' gene patterns can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of those patients who have a high likelihood of response to the drug. The DRP(TM) platform can be used in all cancer types and has been patented for more than 60 anticancer drugs in the US.